Jun 10, 2009
Bavarian prime minister Horst Seehofer visits SuppreMol GmbH during his attendance at the IZB (Innovation and Startup Center for Biotechnology) in Martinsried

May 04, 2009
SuppreMol Announces Start of Phase I Clinical Trial with its lead program SM101

Oct 21, 2008
SuppreMol Announces Expansion of its Management Team and Board Changes

June 1-2, 2009
5th Global Proteins Summit, London/UK

June 17-19, 2009
The Biopharmaceutical Conference in Europe, Monte Carlo

August 24-27, 2009
The Bioprocessing Summit, Cambridge, MA, USA

September 16-18, 2009
BioPharm America 2009, San Francisco, CA, USA

October 27-28, 2009
BioProduction 2009, Barcelona, Spain

October 29-30, 2009
2nd Annual Proteins Congress 2009, Berlin, Germany

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources
Video on Suppremol

SuppreMol GmbH is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

At present, SuppreMol develops drug candidates for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis and Psoriasis. Its lead product SM101 already is in clinical development.

The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry and is located in Martinsried near Munich, Germany.